新闻资讯

BRIEF-S107 million series C raise for HighTide Therapeutics

2023-01-06

source from:The pharma letter


Metabolic and digestive disease specialist HighTide Therapeutics has raised S107 million in aseries C financing led by China's TCM Healthcare Fund, with money also from Yuexiu Fundand Yuthai Fund.


The company, which has a footprint in both China and the USA, is working on multifunctionaltherapies, including lead candidate HTD801, a first-in-class candidate for conditionsincluding type 2 diabetes and non-alcoholic steatohepatitis (NASH).


HighTide will use the money to advance clinical development as well as commercializationand business development.


With a Phase II trial in type 2 diabetes near completion, the company has also initiated mid-stage research in NASH and has secured US Fast Track designation for the candidate in NASHas well as primary sclerosing cholangitis (PSC).
分享到微信朋友圈 ×
打开微信,点击底部的“发现”,
使用“扫一扫”即可将网页分享至朋友圈。

© 2024 HighTide Therapeutics, Inc.

法律声明隐私政策Cookie政策

收起
En

Follow Us

© 2024 HighTide Therapeutics, Inc.